2020
DOI: 10.3389/fcell.2020.607483
|View full text |Cite
|
Sign up to set email alerts
|

The Epithelial-to-Mesenchymal Transition as a Possible Therapeutic Target in Fibrotic Disorders

Abstract: Fibrosis is a chronic and progressive disorder characterized by excessive deposition of extracellular matrix, which leads to scarring and loss of function of the affected organ or tissue. Indeed, the fibrotic process affects a variety of organs and tissues, with specific molecular background. However, two common hallmarks are shared: the crucial role of the transforming growth factor-beta (TGF-β) and the involvement of the inflammation process, that is essential for initiating the fibrotic degeneration. TGF-β … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
88
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 99 publications
(89 citation statements)
references
References 322 publications
1
88
0
Order By: Relevance
“…TGF-β is a well-known inducer of endothelial-to-mesenchymal transition, representing a critical link in the complex interactions between inflammatory stress and endothelial dysfunction. It is involved in a variety of biological processes that drive the formation of fibrosis, accompanying many disease states [62,63]. Our microarray data suggest, for the first time, that HT treatment reduced the IL-1β up-regulated expression of TGF-β2 and β3 in endothelial cells, thus revealing another mechanistic explanation for the anti-inflammatory and vascular beneficial properties attributed to HT, including a potential antifibrotic effect.…”
Section: Discussionmentioning
confidence: 63%
“…TGF-β is a well-known inducer of endothelial-to-mesenchymal transition, representing a critical link in the complex interactions between inflammatory stress and endothelial dysfunction. It is involved in a variety of biological processes that drive the formation of fibrosis, accompanying many disease states [62,63]. Our microarray data suggest, for the first time, that HT treatment reduced the IL-1β up-regulated expression of TGF-β2 and β3 in endothelial cells, thus revealing another mechanistic explanation for the anti-inflammatory and vascular beneficial properties attributed to HT, including a potential antifibrotic effect.…”
Section: Discussionmentioning
confidence: 63%
“…Consistent with the previous results, the activated form of Smad2/3 significantly increased in TGF-β1-treated CCD-18Co cells. Another critical feature of TGF-β1 is the ability to sustain itself through an autocrine loop inducing its release from fibroblast [21]. TGF-β1neosynthesis in activated-CCD-18Co cells was significantly stimulated by the addition of TGF-β1; however, the Vivomixx ® lysates significantly suppressed the stimulation.…”
Section: Discussionmentioning
confidence: 99%
“…Elevated levels of WISP-1 in the renal tubular epithelium of rats were shown to increase the production of fibrotic substances induced by TGFβ ( Yang et al, 2020 ). By upregulating the nuclear expression of bone marrow mesenchymal genes (such as Zeb1, Pai1, and α-SMA) ( DiGregorio, et al, 2020 ), WISP-1 can also promote renal fibrosis and mediate TGF signaling. TGFβ activates Wnt signals by down-regulating the production of DKK-1 ( Akhmetshina et al, 2012 ).…”
Section: Wnt Signaling Pathway and Renal Fibrosismentioning
confidence: 99%